Part 1: Currently Accepted Glaucoma Practice 1. Pathophysiology 2. Epidemiology 3. Diagnosis and investigations 4. Follow-up 5. Treatments 6. Section Summary: Discussion on the major unmet needs of the specialtyPart 2: Pathophysiology and investigation methods 7. Glaucoma epidemiology: the role of genetics and biomarkers 8. Considerations for an efficient screening programmes for glaucoma 9. Ocular perfusion in glaucoma and the role of arterial blood pressure 10. The role of circadian and extrinsic intraocular pressure fluctuations11. Pseudo-exfoliative glaucoma: epidemiology, pathophysiology and their clinical impact12. Retinal and optic nerve micro-perfusion and the role of OCT-A13. Structural testing modalities: cicrumpapillary RNFL, BMO-MRW, macular RNFL or vessel density?14. Statistical considerations on visual field testing: how frequent is frequent-enough?15. Novelties in functional testing: the role of contrast sensitivity, electrophysiology and colour vision16. Section Summary: Diagnosing the grey zone and follow-up considerationsPart 3: Medical and laser therapies17. Social and psychological aspects of treatment adherence18. Topical medications and ocular surface19. Novel pressure-lowering medications and research alternatives20. Novel drug delivery methods21. Matrix metalloproteinase22. Medical lasers, basic principles and core differences23. Physiological principles and effects of SLT; discussion over the LIGHT Trial24. Prophylactic iridotomy in narrow angle glaucoma25. Aqueous dynamics, glaucoma and corneal health (considerations for iridotomies) 26. Section Summary: Recommendations in treatment-naïve open-angle glaucoma, treatment escalation protocols, and patient-specific considerations Part 4: Surgical options27. Anatomical, mechanical and physiological effect of cataract surgery in open and narrow angle glaucoma28. Anatomical considerations on trabecular meshwork, Schlemm's canal and collecting channels29. The role of ocular inflammation, fluid dynamics and bleb morphology in surgical outcomes (including long-term conjunctival sensitization with fibroblast, aqueous inflammatory markers, and effect of aqueous flow on bleb viability; and considerations on early/delayed surgery)30. Aqueous angiography and targeted surgery31. Minimally-invasive glaucoma surgery (MIGS) device design considerations32. Novel approaches to aqueous drainage33. Adjustable drainage devices: benefits and shortcomings34. Implantable intraocular pressure sensors and telemedicine35. Laser-assisted surgery36. Considerations on glaucoma clinical trials 37. Section Summary: Surgical considerations: Finding the best patient-surgeon-procedure matchPart 5: New technologies 38. Artificial intelligence and Big Data: technical considerations and clinical applications39. Detection of apoptosing retinal cells (DARC) in glaucoma40. Neuroprotection and neurostimulation41. Clinical trials in neuroprotection: special considerations42. Neuro-regeneration and stem-cell therapies43. Gene therapy44. Section Summary: Predicting the future of glaucoma practice
